Women & the Timing Question
Timing is part of your plan.
Published position guidance holds that for women under sixty, or within ten years of menopause onset and without contraindications, the benefit-risk balance is favorable for vasomotor symptoms and for maintaining bone density.
Beyond ten years from onset, or past sixty, the balance shifts as absolute risks rise, so your physician weighs your timing carefully.
Risk varies by type, dose, duration, route, timing, and whether a progestogen is used, which is why every plan is individual.
Guidance is explicit that therapy should be individualized with shared decision-making and reassessed periodically, which is exactly how it is run here.
Source: The 2022 hormone therapy position statement of The North American Menopause Society.
